- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
CorEvitas Acquires Pregnancy Data Registry Pregistry
This is the intelligence company's fifth acquisition.
CorEvitas announced the acquisition of Pregistry LLC, a company focused on safety studies during pregnancy.
Pregistry utilizes 70 pregnancy experts to provide reports and studies on healthy pregnancies and births. The group collects data based on clinical, safety, regulatory, marketing, and technology needs and is then shared with individuals, providers, and industry stakeholders. This information is reportedly used by doctors as part of their decisions on what medications and vaccines to prescribe.
In a press release, Dr. Diego Wysznski, founder and chief executive officer of Pregistry, said, “For the last eight years, Pregistry has been a leader in the design and execution of pregnancy exposure registries to fulfill global regulatory commitments, such as mandates from the FDA and the EMA, and other observational studies in the maternal health field, including the world's largest pregnancy registries on COVID-19 vaccines and Covid treatments.”
CorEvitas is an intelligence company to provides a syndicated network of registries. Pregistry is its fifth acquisition.
Continue reading this story here.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
